MOLECULAR DESIGN INTERNATIONAL, INC.

Basic Information

111 South Highland Street
MEMPHIS, TN, 38111-

Company Profile

n/a

Additional Details

Field Value
DUNS: 75592597
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel Topical Therapy for Diabetic Retinopathy using Beta-Adrenergic Receptor Ago

    Amount: $108,399.00

    DESCRIPTION (provided by applicant): The overall goal of our work is to establish the potency and efficacy of a novel 2-adrenergic receptor agonist (compound 49b) in the prevention and/or reversal ...

    STTR Phase I 2011 Department of Health and Human Services
  2. Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

    Amount: $1,196,749.00

    DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degr ...

    SBIR Phase II 2008 Department of Health and Human Services
  3. Topical Skin Treatment to Facilitate Wound Healing in the Aged Population

    Amount: $100,001.00

    DESCRIPTION (provided by applicant): MDI-301 is a synthetic retinoid. MDI-301, like RA, induces collagen synthesis and reduces expression of collagen-degrading matrix metalloproteinases in the skin. T ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Wound Healing Properties of a Non-Irritating Novel 9-cis Retinoid Acid Derivative

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): MDI 301 is a synthetic retinoid that is similar to all-trans retinoic acid (RA) in its ability to stimulate collagen synthesis and inhibit the major collagen-degra ...

    SBIR Phase I 2006 Department of Health and Human Services
  5. NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

    Amount: $1,016,500.00

    DESCRIPTION (provided by applicant): This application represents the Phase II version of SBIR grant R43 AR049621 entitled "Non-Irritating Retinoids for the Treatment of Aging Skin". Studies carried ou ...

    SBIR Phase II 2005 Department of Health and Human Services
  6. NON-IRRITATING RETINOIDS FOR THE TREATMENT OF AGING

    Amount: $99,000.00

    DESCRIPTION (provided by applicant): Molecular Design International, Inc. (MDI) has designed and synthesized three synthetic retinoids based on the removal of the free carboxylic acid proton and re ...

    SBIR Phase I 2003 Department of Health and Human Services
  7. DEVELOPMENT OF MULTI-RECEPTOR LC STATIONARY PHASES

    Amount: $100,000.00

    DESCRIPTION: (Applicant's description) Combinatorial methods for the synthesis of new drug substances require high throughput techniques for evaluation of structure-activity relationshi ...

    STTR Phase I 2001 Department of Health and Human Services
  8. Alpha Adrenergic Agonists for CPR

    Amount: $72,595.00

    In the United States alone, approximately 450,000 people yearly suffer a cardiac arrest outsidethe hospital. Less than 10% of these patients are discharged from the hospital alive, and of these,approx ...

    SBIR Phase I 1994 Department of Health and Human Services
  9. TOPICAL PRODRUGS FOR THE TREATMENT OF PSORIASIS

    Amount: $500,000.00

    PSORIASIS IS A DISEASE THAT AFFECTS MILLIONS OF AMERICANS WITH CHRONIC RECURRENT EXACERBATIONS AND REMISSIONS THAT AREEMOTIONALLY AND PHYSICALLY DEBILITATING. SEVERAL TREATMENTSARE AVAILABLE, BUT IN M ...

    SBIR Phase II 1991 Department of Health and Human Services
  10. DEVELOPMENT OF ELASTASE INHIBITORS TO TREAT EMPHYSEMA

    Amount: $50,000.00

    THE GOAL OF THIS PROJECT IS TO DEVELOP A SYNTHETIC INHIBITOR OF ELASTASE THAT WILL BE EFFECTIVE AND SAFE IN THE TREATMENT OF EMPHYSEMA. TWO DIFFERENT LABORATORIES REPORTED THAT CHLOROMETHYL KETONE (CM ...

    SBIR Phase I 1991 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government